Answers are grounded in this paper and cite their sources.
Findings demonstrate RB-BC suppresses tumor growth and enhances p53-mediated apoptosis in breast cancer, suggesting new therapeutic options.
Breast cancer persists as the most prevalent malignancy and principal contributor to cancer‐associated mortality among women worldwide, exhibiting marked disease heterogeneity and therapeutic resistance. Consequently, the development of novel therapeutic agents remains imperative. Ribociclib, a cyclin‐dependent kinase 4/6 inhibitor, has emerged as a focus in adjuvant breast cancer research due to its mechanism of cell cycle arrest induction. Building upon this rationale, we designed and synthesized a novel Ribociclib derivative, RB‐BC, systematically investigating its anti‐neoplastic efficacy and molecular mechanisms in breast cancer through an integrated in vitro and in vivo experimental system. The compound's anti‐proliferative effects were quantitatively assessed via 3‐(4,5‐dimethylthiazol‐2‐yl)‐2,5‐diphenyltetrazolium bromide assays, 5‐ethynyl‐2’‐deoxyuridine incorporation assays, and colony formation assays. Functional characterization through cell adhesion assays, scratch wound healing assays, and Transwell invasion assays demonstrated RB‐BC's dose‐dependent suppression of tumor migration and invasion. Mechanistic analyses, conducted via RNA sequencing and Western blotting, revealed that its anti‐tumor activity primarily stems from the activation of the p53 pathway, which induces caspase‐3‐mediated apoptosis in breast cancer cells. Machine learning algorithms identified p53‐associated genetic signatures, and subsequent bioinformatics analyses elucidated their significant correlation with immune cell infiltration dynamics in the tumor microenvironment. Moreover, RB‐BC effectively suppressed tumor growth in vivo and significantly disrupted angiogenesis in the chick chorioallantoic membrane assay. In summary, the Ribociclib‐derived compound, RB‐BC, demonstrates compelling potential as a candidate therapeutic agent for breast cancer.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: